Pertuzumab biosimilar - CSPC ZhongQi Pharmaceutical Technology
Alternative Names: SYSA-1901Latest Information Update: 21 Aug 2024
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III HER2 positive breast cancer
Most Recent Events
- 21 Aug 2024 CSPC Pharmaceutical Group Limited announces its intention to file for regulatory approval for Breast cancer in China in 2026
- 09 Feb 2023 Phase-III clinical trials in HER2-positive-breast-cancer (Late-stage disease, Neoadjuvant therapy) in China (IV) (NCT05720026)
- 09 Feb 2023 Phase-III clinical trials in HER2-positive-breast-cancer (Neoadjuvant therapy, Early-stage disease) in China (IV) (NCT05720026)